The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 2, 1999, Pages 81-86

  Hahn, Lennart ^a   Mattsson, L A ^b   Andersson, B ^a   Tengborn, L ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sahlgrenska University Hospital East ^*

Author keywords

Coagulation; Diabetes; Fibrinolysis; Oestrogen replacement therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; ESTRADIOL; ESTROFEM; ESTROGEN; FIBRINOGEN; METFORMIN; NORETHISTERONE ACETATE; ORAL ANTIDIABETIC AGENT; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; TRISEQUENS; VON WILLEBRAND FACTOR;

ADULT; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0343179246     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199903000-00004     Document Type: Review

References (36)

1. 1. Kannel WB, McGee DL. Diabetes and cardiovascular disease - The Framingham Study. JAMA 1979; 241: 2035-2038.
2. 2. Haffner SM, Miettinen H. Insulin resistance, implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-162.
3. 3. Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-551.
4. 4. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
5. 5. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
6. 6. Barrett-Connor E, Bush T. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
7. 7. Falkeborn M, Persson I, Adami HO, Bergström R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-828.
8. 8. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
9. 9. Andersson B, Mattsson L-Å, Hahn L, Mårin P, Lapidus L, Holm G, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638-643.
10. 10. World Health Organization Expert Committee. Second report on diabetes mellitus. Technical Report. Geneva: World Health Organization; 1980. pp. 1-80.
11. 11. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47/50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
12. 12. Walsh BW, Schiff I, Rosner B, Grenberg L, Ravnikar V, Sacks FM. Effect of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
13. 13. Barren-Connor E, Laakso M. Ischaemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531-534.
14. 14. Best PJM, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998; 128: 285-288.
15. 15. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al. Association between increased estrogen status and increased fibnnolytic potential in the Framingham offspring study. Circulation 1995; 91: 1952-1958.
16. 16. Gilabert J, Estellés A, Cano A, Espana F, Barrachina R, Grancha S, et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-1854.
17. 17. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Delia Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in post menopausal women. Thromb Res 1991; 62: 1-8.
18. 18. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-423.
19. 19. Fox J, George AJ, Newton JR, Parsons AD, Stuart GK, Stuart J, et al. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55-64.
20. 20. Lindoff C, Peterson F, Lecander I, Martinsson G, Åstedt B. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996; 24: 43-50.
21. 21. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Int Med 1998; 158: 617-621.
22. 22. Brussard HE, Leuven JA, Frölich M, Kluft C, Krans HMJ. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40: 843-849.
23. 23. Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. Arterioscler Thromb 1993; 13: 1865-1873.
24. 24. Mykkönen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264-1271.
25. 25. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.
26. 26. Haffner SM, Dunn JF, Katz MS. Relationship of sex-hormone-binding globulin to lipid, lipoprotein, glucose and insulin concentrations in postmenopausal women. Metabolism 1992; 41: 278-284.
27. 27. Lapidus L, Lindstedt G, Lundberg P-A, Bengtsson C, Gredmark T. Concentrations of sex-hormone-binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986; 32: 146-152.
28. 28. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 290-293.
29. 29. The PEPI trial group. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
30. 30. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo CW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
31. 31. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone therapy. Lancet 1996; 348: 977-980.
32. 32. Jick H, Derby LE, Myers MW, Vasilaakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
33. 33. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FF, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-988.
34. 34. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-395.
35. 35. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987-995.
36. 36. Cortellaro M, Nencioni T, Boschetti C, Ortolani S, Buzzi F, Francucci B, et al. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment. Eur J Clin Pharmacol 1991; 41: 555-559.